The first four weeks are where the protocol either lands or evaporates. The compounds are correct, the doses are correct, the mechanism is sound — and yet most people who start a gut-repair stack don't finish Week 3. The collapse point isn't biology. It's the moment the daily rhythm becomes inconvenient and the user starts skipping. This chapter locks the rhythm before that happens.
Phase 1 is doing two specific things at the cellular level. BPC-157 in the abdominal fat is concentrating peptide near the intestinal vasculature — the practitioner corpus is clear that for leaky-gut and IBS work, injection site dictates outcome. BPC-157 was originally isolated from gastric juice, and its angiogenic, nitric-oxide-modulating, and tight-junction-restorative effects all run hottest in the tissue closest to the injection. Belly fat is not arbitrary. It's the systemic delivery point that lands the highest local concentration in the gut wall. KPV is shutting down NF-κB translocation in the mucosal immune layer — the same inflammatory cascade driving TNF-α, IL-6, and IL-1β release that keeps the gut barrier in a permanently leaky state. The two compounds attack the problem from complementary angles: BPC-157 rebuilds the wall, KPV stops the fire that's burning it down. Practitioner consensus considers this one of the most powerful gut-healing combinations available.
The reason this stack runs for four weeks at this phase — not two, not eight — is that chronic gut conditions take 2-4 weeks to show meaningful tight-junction repair, and a full 4-6 week cycle is needed for comprehensive assessment. Acute responses show in 3-7 days. Chronic responses lag. Setting the clock to four weeks before you re-evaluate is what separates protocol discipline from compound chasing.
A note on route, because the chapter subtitle invites the question. The substrate is split, and you should know exactly where the split is. Injectable BPC-157 (subcutaneous, abdominal fat) is the only route with published systemic effects — tendon repair, neuroprotection, anti-inflammatory action all came from injectable studies. Companies selling generic oral BPC-157 capsules are selling expensive amino acids; the peptide chain is destroyed by proteolytic enzymes and first-pass liver metabolism before it reaches circulation. The carve-out the practitioner corpus describes: BPC-157 arginate salt formulations, designed to survive gastric acidity, are described as the best route specifically for gut-local issues — IBD, colitis, leaky gut — where you want the peptide acting on the lumen itself, not systemically. For Phase 1 here, you can run either: injectable SubQ into abdominal fat for systemic + local delivery, or oral arginate form for gut-local-only. Most Phase 1 stacks use injectable because KPV is already being injected and the syringe is out anyway.
Phase 1 stack — Weeks 1-4
| Compound | Dose | Route | Frequency | Evidence Tier | Notes |
|---|---|---|---|---|---|
| BPC-157 | 250 mcg (60 kg) → 450 mcg (90 kg), weight-scaled | SubQ, abdominal fat (rotate clockwise around navel, ≥2 cm from navel) | 1-2x daily | Expert | 5 mg vial reconstituted in 2 mL BAC water = 2,500 mcg/mL. 250 mcg = 10 units on a 100-unit insulin syringe. 28G 1/2" slin pin. Refrigerate after reconstitution, use within 28-30 days. |
| BPC-157 (arginate, alternative route) | 250-500 mcg | Oral capsule, fasted morning | 1-2x daily | Expert | Only the arginate salt survives gastric acid. Generic oral powder = inactive. Use if the user wants gut-local delivery without injection. |
| KPV | 200 mcg → 500 mcg | SubQ | Daily | Expert | Conservative start at 200 mcg daily for 7 days to assess tolerance, then increase to 500 mcg daily for the remainder of the 4-6 week cycle. Cycle 4-6 weeks on, 2-4 weeks off. |
The daily rhythm — what it actually looks like
Morning, fasted, before coffee. Both injections go in together. Pull KPV first into the syringe, then BPC-157 into the same syringe if reconstitution concentrations allow — or two separate slin pins, back-to-back, into adjacent abdominal sites. Pinch belly fat, insert at 45° or 90° depending on subcutaneous depth, push slowly and smoothly (fast injection causes tissue irritation and sub-optimal absorption), withdraw at the same angle, light pressure with an alcohol swab if needed. No rubbing on the KPV site. For the BPC-157 site, massage the injection area for 30-60 seconds — the practitioner corpus describes this as improving local absorption into the underlying tissue.
Site rotation: clockwise pattern around the navel, staying at least 2 cm out. Day 1 upper right, Day 2 upper left, Day 3 lower left, Day 4 lower right, Day 5 back to upper right with a slight offset. This prevents lipodystrophy, bruising, and the hardened tissue that develops when injection sites are reused.
If you want a second BPC-157 dose, run it 8-12 hours after the morning dose — pre-bed is convenient and gives a second exposure window during the body's repair-dominant phase. KPV stays once daily.
What you should feel — Week-by-week
- Days 1-7: Likely nothing dramatic. The KPV titration is happening. The corpus describes this as the assessment window — you're confirming tolerance, not chasing effect. Some users report a subtle bloating reduction by Day 5-7. Most feel nothing yet. That's normal.
- Days 8-14: First signals usually appear here for acute-pattern users. Reduced post-meal bloating, less urgency, sometimes a noticeable drop in brain-fog that tracks gut inflammation. Chronic-pattern users typically feel nothing yet — the 2-4 week lag for chronic conditions is real.
- Days 15-21: This is where chronic users start to register changes. Stool consistency normalizing, less reactivity to historical trigger foods (don't test deliberately — track what happens incidentally), reduced systemic inflammation markers if you're tracking them subjectively (joint stiffness, skin clarity, sleep quality).
- Days 22-28: Assessment window. By Week 4 the corpus expects meaningful improvement in chronic conditions. Not resolution — improvement. If you're seeing zero change by Day 28 with verified compliance, that's the signal for the Module 9 decision tree, not a reason to extend Phase 1 unchanged.
What's NOT happening yet
- Full tight-junction restoration. Zonulin and lipopolysaccharide markers, if you're pulling them, will still be elevated. Tight-junction protein turnover takes longer than four weeks. Phase 2 is what completes the rebuild.
- Microbiome restoration. Neither BPC-157 nor KPV repopulates beneficial flora. They reduce the inflammatory environment that was suppressing it, but actual microbiome composition shifts lag the inflammation reduction by weeks to months.
- Food tolerance reset. Resist the urge to deliberately re-introduce trigger foods to "test." Phase 1 is reducing the inflammatory baseline. Re-introductions belong in Phase 2 or maintenance, not in the middle of an active repair cycle.
- Systemic effects beyond the gut. Skin, mood, sleep often improve secondarily, but if you're running this stack expecting joint or tendon outcomes, you're using the wrong protocol. The injection site is abdominal for a reason.
Research describes this rhythm. Track it. Adjust at Week 4, not before.